Radioguided parathyroidectomy for tertiary hyperparathyroidism

Abstract Background Tertiary hyperparathyroidism (3HPT) is defined as the persistent hyperproduction of parathyroid hormone and resulting hypercalcemia after renal transplantation. Here, we examine the utility of radioguided parathyroidectomy (RGP) in patients with 3HPT. Materials and methods We rev...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of surgical research 2015-05, Vol.195 (2), p.406-411
Hauptverfasser: Somnay, Yash R., BS, Weinlander, Eric, BA, Alfhefdi, Amal, MD, Schneider, David, MD, MS, Sippel, Rebecca S., MD, Chen, Herbert, MD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 411
container_issue 2
container_start_page 406
container_title The Journal of surgical research
container_volume 195
creator Somnay, Yash R., BS
Weinlander, Eric, BA
Alfhefdi, Amal, MD
Schneider, David, MD, MS
Sippel, Rebecca S., MD
Chen, Herbert, MD
description Abstract Background Tertiary hyperparathyroidism (3HPT) is defined as the persistent hyperproduction of parathyroid hormone and resulting hypercalcemia after renal transplantation. Here, we examine the utility of radioguided parathyroidectomy (RGP) in patients with 3HPT. Materials and methods We reviewed a prospective surgery database containing 80 3HPT patients who underwent RGP from January 2001–July 2014 at our institution. We evaluated patient demographics, operative management, radioguided neoprobe utilization, and operative outcomes. Data are reported as mean ± standard error of the mean. Results The mean age of the patients was 52 ± 1 y, and 46% were male. A total of 69 patients had hyperplasia and received subtotal parathyroidectomy, whereas 5 patients had double adenomas and 6 patients had single adenomas. The average calcium level among 3HPT patients was 10.8 ± 0.1 mg/dL preoperatively and 8.7 ± 0.1 mg/dL postoperatively. In vivo radioguided counts normalized to background counts averaged 145 ± 4%, whereas ex vivo counts normalized to background counts averaged 69 ± 5%. All but one ex vivo count was >20%. Ectopically located glands were successfully localized in 38 patients using the gamma probe. Ex vivo percentage did not correlate with parathyroid gland weight, preoperative parathyroid hormone, or preoperative calcium. Our radioguided approach achieved normocalcemia in 96% of 3HPT patients undergoing RGP; two patients developed recurrent disease. Conclusions In this series, all enlarged parathyroid glands were localized and resected using the gamma probe. Thus, RGP reliably localizes adenomatous, hyperplastic, and ectopically located glands in patients with 3HPT, resulting in high cure rate after resection.
doi_str_mv 10.1016/j.jss.2015.02.015
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4422627</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0022480415001262</els_id><sourcerecordid>1677884595</sourcerecordid><originalsourceid>FETCH-LOGICAL-c506t-9ea54c599b8a0b655f9de8f2dfee622867c4bd3166b37c20a6df07758f65acf3</originalsourceid><addsrcrecordid>eNp9kU9r3DAQxUVpabZpP0AvZY-92B3JlmRTWCih_yBQSHIXsjTKyrWtrWQH_O2rZdOQ5pDTMOi9p5nfEPKeQkmBik992adUMqC8BFbm8oJsKLS8aISsXpINAGNF3UB9Rt6k1EPuW1m9JmeMSwmy4huyu9LWh9vFW7Tbg4563q8x5M7MYVy3LsTtjHH2Oq7b_XrA-Ejj0_iWvHJ6SPjuvp6Tm29fby5-FJe_vv-8-HJZGA5iLlrUvDa8bbtGQyc4d63FxjHrEAVjeVxTd7aiQnSVNAy0sA6k5I0TXBtXnZPdKfawdCNag9Mc9aAO0Y95MBW0V_-_TH6vbsOdqmvGBJM54ON9QAx_FkyzGn0yOAx6wrAkRYWUTVPzlmcpPUlNDClFdA_fUFBH7KpXGbs6YlfAVC7Z8-HxfA-Of5yz4PNJgBnSnceokvE4GbQ-ZtTKBv9s_O6J2wx-8kYPv3HF1IclTpm-oiplg7o-3v14dsoBaN6_-guKwaqz</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1677884595</pqid></control><display><type>article</type><title>Radioguided parathyroidectomy for tertiary hyperparathyroidism</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Somnay, Yash R., BS ; Weinlander, Eric, BA ; Alfhefdi, Amal, MD ; Schneider, David, MD, MS ; Sippel, Rebecca S., MD ; Chen, Herbert, MD</creator><creatorcontrib>Somnay, Yash R., BS ; Weinlander, Eric, BA ; Alfhefdi, Amal, MD ; Schneider, David, MD, MS ; Sippel, Rebecca S., MD ; Chen, Herbert, MD</creatorcontrib><description>Abstract Background Tertiary hyperparathyroidism (3HPT) is defined as the persistent hyperproduction of parathyroid hormone and resulting hypercalcemia after renal transplantation. Here, we examine the utility of radioguided parathyroidectomy (RGP) in patients with 3HPT. Materials and methods We reviewed a prospective surgery database containing 80 3HPT patients who underwent RGP from January 2001–July 2014 at our institution. We evaluated patient demographics, operative management, radioguided neoprobe utilization, and operative outcomes. Data are reported as mean ± standard error of the mean. Results The mean age of the patients was 52 ± 1 y, and 46% were male. A total of 69 patients had hyperplasia and received subtotal parathyroidectomy, whereas 5 patients had double adenomas and 6 patients had single adenomas. The average calcium level among 3HPT patients was 10.8 ± 0.1 mg/dL preoperatively and 8.7 ± 0.1 mg/dL postoperatively. In vivo radioguided counts normalized to background counts averaged 145 ± 4%, whereas ex vivo counts normalized to background counts averaged 69 ± 5%. All but one ex vivo count was &gt;20%. Ectopically located glands were successfully localized in 38 patients using the gamma probe. Ex vivo percentage did not correlate with parathyroid gland weight, preoperative parathyroid hormone, or preoperative calcium. Our radioguided approach achieved normocalcemia in 96% of 3HPT patients undergoing RGP; two patients developed recurrent disease. Conclusions In this series, all enlarged parathyroid glands were localized and resected using the gamma probe. Thus, RGP reliably localizes adenomatous, hyperplastic, and ectopically located glands in patients with 3HPT, resulting in high cure rate after resection.</description><identifier>ISSN: 0022-4804</identifier><identifier>EISSN: 1095-8673</identifier><identifier>DOI: 10.1016/j.jss.2015.02.015</identifier><identifier>PMID: 25770735</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Female ; Gamma probe ; Humans ; Hyperparathyroidism - blood ; Hyperparathyroidism - surgery ; Male ; Middle Aged ; Parathyroid Hormone - blood ; Parathyroidectomy - adverse effects ; Parathyroidectomy - methods ; Radioguided parathyroidectomy ; Radiopharmaceuticals ; Surgery ; Technetium (99mTc) sestamibi ; Technetium Tc 99m Sestamibi ; Tertiary hyperparathyroidism</subject><ispartof>The Journal of surgical research, 2015-05, Vol.195 (2), p.406-411</ispartof><rights>Elsevier Inc.</rights><rights>2015 Elsevier Inc.</rights><rights>Copyright © 2015 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c506t-9ea54c599b8a0b655f9de8f2dfee622867c4bd3166b37c20a6df07758f65acf3</citedby><cites>FETCH-LOGICAL-c506t-9ea54c599b8a0b655f9de8f2dfee622867c4bd3166b37c20a6df07758f65acf3</cites><orcidid>0000-0001-9787-7316</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0022480415001262$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25770735$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Somnay, Yash R., BS</creatorcontrib><creatorcontrib>Weinlander, Eric, BA</creatorcontrib><creatorcontrib>Alfhefdi, Amal, MD</creatorcontrib><creatorcontrib>Schneider, David, MD, MS</creatorcontrib><creatorcontrib>Sippel, Rebecca S., MD</creatorcontrib><creatorcontrib>Chen, Herbert, MD</creatorcontrib><title>Radioguided parathyroidectomy for tertiary hyperparathyroidism</title><title>The Journal of surgical research</title><addtitle>J Surg Res</addtitle><description>Abstract Background Tertiary hyperparathyroidism (3HPT) is defined as the persistent hyperproduction of parathyroid hormone and resulting hypercalcemia after renal transplantation. Here, we examine the utility of radioguided parathyroidectomy (RGP) in patients with 3HPT. Materials and methods We reviewed a prospective surgery database containing 80 3HPT patients who underwent RGP from January 2001–July 2014 at our institution. We evaluated patient demographics, operative management, radioguided neoprobe utilization, and operative outcomes. Data are reported as mean ± standard error of the mean. Results The mean age of the patients was 52 ± 1 y, and 46% were male. A total of 69 patients had hyperplasia and received subtotal parathyroidectomy, whereas 5 patients had double adenomas and 6 patients had single adenomas. The average calcium level among 3HPT patients was 10.8 ± 0.1 mg/dL preoperatively and 8.7 ± 0.1 mg/dL postoperatively. In vivo radioguided counts normalized to background counts averaged 145 ± 4%, whereas ex vivo counts normalized to background counts averaged 69 ± 5%. All but one ex vivo count was &gt;20%. Ectopically located glands were successfully localized in 38 patients using the gamma probe. Ex vivo percentage did not correlate with parathyroid gland weight, preoperative parathyroid hormone, or preoperative calcium. Our radioguided approach achieved normocalcemia in 96% of 3HPT patients undergoing RGP; two patients developed recurrent disease. Conclusions In this series, all enlarged parathyroid glands were localized and resected using the gamma probe. Thus, RGP reliably localizes adenomatous, hyperplastic, and ectopically located glands in patients with 3HPT, resulting in high cure rate after resection.</description><subject>Female</subject><subject>Gamma probe</subject><subject>Humans</subject><subject>Hyperparathyroidism - blood</subject><subject>Hyperparathyroidism - surgery</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Parathyroid Hormone - blood</subject><subject>Parathyroidectomy - adverse effects</subject><subject>Parathyroidectomy - methods</subject><subject>Radioguided parathyroidectomy</subject><subject>Radiopharmaceuticals</subject><subject>Surgery</subject><subject>Technetium (99mTc) sestamibi</subject><subject>Technetium Tc 99m Sestamibi</subject><subject>Tertiary hyperparathyroidism</subject><issn>0022-4804</issn><issn>1095-8673</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9r3DAQxUVpabZpP0AvZY-92B3JlmRTWCih_yBQSHIXsjTKyrWtrWQH_O2rZdOQ5pDTMOi9p5nfEPKeQkmBik992adUMqC8BFbm8oJsKLS8aISsXpINAGNF3UB9Rt6k1EPuW1m9JmeMSwmy4huyu9LWh9vFW7Tbg4563q8x5M7MYVy3LsTtjHH2Oq7b_XrA-Ejj0_iWvHJ6SPjuvp6Tm29fby5-FJe_vv-8-HJZGA5iLlrUvDa8bbtGQyc4d63FxjHrEAVjeVxTd7aiQnSVNAy0sA6k5I0TXBtXnZPdKfawdCNag9Mc9aAO0Y95MBW0V_-_TH6vbsOdqmvGBJM54ON9QAx_FkyzGn0yOAx6wrAkRYWUTVPzlmcpPUlNDClFdA_fUFBH7KpXGbs6YlfAVC7Z8-HxfA-Of5yz4PNJgBnSnceokvE4GbQ-ZtTKBv9s_O6J2wx-8kYPv3HF1IclTpm-oiplg7o-3v14dsoBaN6_-guKwaqz</recordid><startdate>20150515</startdate><enddate>20150515</enddate><creator>Somnay, Yash R., BS</creator><creator>Weinlander, Eric, BA</creator><creator>Alfhefdi, Amal, MD</creator><creator>Schneider, David, MD, MS</creator><creator>Sippel, Rebecca S., MD</creator><creator>Chen, Herbert, MD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9787-7316</orcidid></search><sort><creationdate>20150515</creationdate><title>Radioguided parathyroidectomy for tertiary hyperparathyroidism</title><author>Somnay, Yash R., BS ; Weinlander, Eric, BA ; Alfhefdi, Amal, MD ; Schneider, David, MD, MS ; Sippel, Rebecca S., MD ; Chen, Herbert, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c506t-9ea54c599b8a0b655f9de8f2dfee622867c4bd3166b37c20a6df07758f65acf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Female</topic><topic>Gamma probe</topic><topic>Humans</topic><topic>Hyperparathyroidism - blood</topic><topic>Hyperparathyroidism - surgery</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Parathyroid Hormone - blood</topic><topic>Parathyroidectomy - adverse effects</topic><topic>Parathyroidectomy - methods</topic><topic>Radioguided parathyroidectomy</topic><topic>Radiopharmaceuticals</topic><topic>Surgery</topic><topic>Technetium (99mTc) sestamibi</topic><topic>Technetium Tc 99m Sestamibi</topic><topic>Tertiary hyperparathyroidism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Somnay, Yash R., BS</creatorcontrib><creatorcontrib>Weinlander, Eric, BA</creatorcontrib><creatorcontrib>Alfhefdi, Amal, MD</creatorcontrib><creatorcontrib>Schneider, David, MD, MS</creatorcontrib><creatorcontrib>Sippel, Rebecca S., MD</creatorcontrib><creatorcontrib>Chen, Herbert, MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of surgical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Somnay, Yash R., BS</au><au>Weinlander, Eric, BA</au><au>Alfhefdi, Amal, MD</au><au>Schneider, David, MD, MS</au><au>Sippel, Rebecca S., MD</au><au>Chen, Herbert, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radioguided parathyroidectomy for tertiary hyperparathyroidism</atitle><jtitle>The Journal of surgical research</jtitle><addtitle>J Surg Res</addtitle><date>2015-05-15</date><risdate>2015</risdate><volume>195</volume><issue>2</issue><spage>406</spage><epage>411</epage><pages>406-411</pages><issn>0022-4804</issn><eissn>1095-8673</eissn><abstract>Abstract Background Tertiary hyperparathyroidism (3HPT) is defined as the persistent hyperproduction of parathyroid hormone and resulting hypercalcemia after renal transplantation. Here, we examine the utility of radioguided parathyroidectomy (RGP) in patients with 3HPT. Materials and methods We reviewed a prospective surgery database containing 80 3HPT patients who underwent RGP from January 2001–July 2014 at our institution. We evaluated patient demographics, operative management, radioguided neoprobe utilization, and operative outcomes. Data are reported as mean ± standard error of the mean. Results The mean age of the patients was 52 ± 1 y, and 46% were male. A total of 69 patients had hyperplasia and received subtotal parathyroidectomy, whereas 5 patients had double adenomas and 6 patients had single adenomas. The average calcium level among 3HPT patients was 10.8 ± 0.1 mg/dL preoperatively and 8.7 ± 0.1 mg/dL postoperatively. In vivo radioguided counts normalized to background counts averaged 145 ± 4%, whereas ex vivo counts normalized to background counts averaged 69 ± 5%. All but one ex vivo count was &gt;20%. Ectopically located glands were successfully localized in 38 patients using the gamma probe. Ex vivo percentage did not correlate with parathyroid gland weight, preoperative parathyroid hormone, or preoperative calcium. Our radioguided approach achieved normocalcemia in 96% of 3HPT patients undergoing RGP; two patients developed recurrent disease. Conclusions In this series, all enlarged parathyroid glands were localized and resected using the gamma probe. Thus, RGP reliably localizes adenomatous, hyperplastic, and ectopically located glands in patients with 3HPT, resulting in high cure rate after resection.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25770735</pmid><doi>10.1016/j.jss.2015.02.015</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-9787-7316</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-4804
ispartof The Journal of surgical research, 2015-05, Vol.195 (2), p.406-411
issn 0022-4804
1095-8673
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4422627
source MEDLINE; Elsevier ScienceDirect Journals
subjects Female
Gamma probe
Humans
Hyperparathyroidism - blood
Hyperparathyroidism - surgery
Male
Middle Aged
Parathyroid Hormone - blood
Parathyroidectomy - adverse effects
Parathyroidectomy - methods
Radioguided parathyroidectomy
Radiopharmaceuticals
Surgery
Technetium (99mTc) sestamibi
Technetium Tc 99m Sestamibi
Tertiary hyperparathyroidism
title Radioguided parathyroidectomy for tertiary hyperparathyroidism
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T00%3A57%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radioguided%20parathyroidectomy%20for%20tertiary%20hyperparathyroidism&rft.jtitle=The%20Journal%20of%20surgical%20research&rft.au=Somnay,%20Yash%20R.,%20BS&rft.date=2015-05-15&rft.volume=195&rft.issue=2&rft.spage=406&rft.epage=411&rft.pages=406-411&rft.issn=0022-4804&rft.eissn=1095-8673&rft_id=info:doi/10.1016/j.jss.2015.02.015&rft_dat=%3Cproquest_pubme%3E1677884595%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1677884595&rft_id=info:pmid/25770735&rft_els_id=1_s2_0_S0022480415001262&rfr_iscdi=true